ES2039233T5 - Procedimientos para la produccion de glicoproteinas del citomegalovirus humano (hcmv), anticuerpos correspondientes y vacunas del hcmv, y vectores recombinantes para los mismos. - Google Patents
Procedimientos para la produccion de glicoproteinas del citomegalovirus humano (hcmv), anticuerpos correspondientes y vacunas del hcmv, y vectores recombinantes para los mismos.Info
- Publication number
- ES2039233T5 ES2039233T5 ES87302001T ES87302001T ES2039233T5 ES 2039233 T5 ES2039233 T5 ES 2039233T5 ES 87302001 T ES87302001 T ES 87302001T ES 87302001 T ES87302001 T ES 87302001T ES 2039233 T5 ES2039233 T5 ES 2039233T5
- Authority
- ES
- Spain
- Prior art keywords
- hcmv
- glycoproteins
- production
- procedures
- recombinant vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE HAN IDENTIFICADO LAS GLICOPROTEINAS B Y H DE HCMV. LA PROTEINA GB ESTA CODIFICADA POR EL ADN EN EL FRAGMENTO F DEL HIND III DEL GENOMA HCMV SITUADO ENTRE LAS BASES 1378 Y 4095 DEL LIGANDO F/D. LA PROTEINA GH ESTA CODIFICADA POR EL ADN EN EL FRAGMENTO L DEL HING III SITUADA ENTRE LAS BASES 228 Y 2456 DEL LIGANDO L/D. LOS GENES HAN SIDO INCORPORADOS EN LOS VECTORES DE LA VACUNA RECOMBINANTE Y EXPRESADOS EN LOS ANIMALES HOSPEDADORES PARA INCREMENTAR EL ANTICUERPO NEUTRALIZANTE DEL HCMV INDICANDO ASI EL POTENCIAL DE LA VACUNA. LAS GLICOPROTEINAS TAMBIEN PUEDEN SER UTILIZADAS EN UNA GRAN VARIEDAD DE VIAS DIFERENTES, COMO VACUNA O EN LA PRODUCCION, PURIFICACION O DETECCION DEL ANTICUERPO HCMV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB868605646A GB8605646D0 (en) | 1986-03-07 | 1986-03-07 | Vaccines |
GB868621081A GB8621081D0 (en) | 1986-03-07 | 1986-09-01 | Vaccines |
GB868629988A GB8629988D0 (en) | 1986-12-16 | 1986-12-16 | Vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2039233T3 ES2039233T3 (es) | 1993-09-16 |
ES2039233T5 true ES2039233T5 (es) | 1998-07-16 |
Family
ID=27262944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES87302001T Expired - Lifetime ES2039233T5 (es) | 1986-03-07 | 1987-03-09 | Procedimientos para la produccion de glicoproteinas del citomegalovirus humano (hcmv), anticuerpos correspondientes y vacunas del hcmv, y vectores recombinantes para los mismos. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0236145B2 (es) |
JP (4) | JP3254127B2 (es) |
CA (1) | CA1335429C (es) |
DE (1) | DE3768833D1 (es) |
ES (1) | ES2039233T5 (es) |
GB (1) | GB2194538B (es) |
HK (1) | HK153395A (es) |
WO (1) | WO1987005326A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5153311A (en) * | 1986-11-24 | 1992-10-06 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus gCII |
US5124440A (en) * | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
US5248768A (en) * | 1986-11-24 | 1993-09-28 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus |
WO1989001628A1 (en) * | 1987-08-07 | 1989-02-23 | The Children's Hospital, Incorporated | Monoclonal antibodies reactive with cytomegalovirus glycoprotein a |
AU641121B2 (en) * | 1988-01-29 | 1993-09-16 | Chiron Corporation | Recombinant CMV neutralizing proteins |
US5547834A (en) * | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
WO1989010965A2 (en) * | 1988-05-03 | 1989-11-16 | The Upjohn Company | Glycoprotein h of herpes viruses |
US5552143A (en) * | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5180813A (en) * | 1989-03-24 | 1993-01-19 | University Of Iowa Research Foundation | Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins |
EP0389286B1 (en) * | 1989-03-24 | 1996-07-10 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) * | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
WO1991004277A1 (en) * | 1989-09-14 | 1991-04-04 | Children's Biomedical Research Institute | Monoclonal antibodies specific to cytomegalovirus glycoprotein |
US5997878A (en) * | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
JPH0868587A (ja) * | 1994-08-30 | 1996-03-12 | Hitachi Ltd | 冷蔵庫の機械室構造 |
WO1997040165A1 (en) | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
DK0960336T3 (da) * | 1996-07-12 | 2003-02-10 | Organon Teknika Bv | Peptidreagens til påvisning af humant cytomelagovirus (CMV) |
EP1670507A4 (en) | 2003-09-12 | 2007-10-17 | Antigenics Inc | VACCINE FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY HERPES SIMPLEX VIRUS |
US7491490B2 (en) * | 2004-05-12 | 2009-02-17 | Wisconsin Alumni Research Foundation | Cytomegalovirus disintegrin-like peptides |
TW201738562A (zh) * | 2009-05-28 | 2017-11-01 | 亞培生物股份有限公司 | 體外病原體檢驗技術 |
CA2779459A1 (en) * | 2009-10-30 | 2011-05-05 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
-
1987
- 1987-03-06 CA CA000531353A patent/CA1335429C/en not_active Expired - Lifetime
- 1987-03-09 GB GB8724676A patent/GB2194538B/en not_active Expired - Lifetime
- 1987-03-09 EP EP87302001A patent/EP0236145B2/en not_active Expired - Lifetime
- 1987-03-09 WO PCT/GB1987/000164 patent/WO1987005326A1/en active Application Filing
- 1987-03-09 DE DE8787302001T patent/DE3768833D1/de not_active Expired - Lifetime
- 1987-03-09 ES ES87302001T patent/ES2039233T5/es not_active Expired - Lifetime
-
1995
- 1995-09-28 HK HK153395A patent/HK153395A/xx not_active IP Right Cessation
-
1996
- 1996-03-26 JP JP09774096A patent/JP3254127B2/ja not_active Expired - Lifetime
- 1996-03-26 JP JP09774196A patent/JP3254128B2/ja not_active Expired - Lifetime
-
1997
- 1997-10-01 JP JP26908697A patent/JP3217019B2/ja not_active Expired - Lifetime
-
2001
- 2001-09-27 JP JP2001298642A patent/JP3506683B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB8724676D0 (en) | 1987-11-25 |
ES2039233T3 (es) | 1993-09-16 |
CA1335429C (en) | 1995-05-02 |
JPH0994095A (ja) | 1997-04-08 |
GB2194538B (en) | 1990-10-24 |
GB2194538A (en) | 1988-03-09 |
WO1987005326A1 (en) | 1987-09-11 |
EP0236145B1 (en) | 1991-03-27 |
EP0236145B2 (en) | 1998-03-11 |
JP2002176992A (ja) | 2002-06-25 |
EP0236145A1 (en) | 1987-09-09 |
JPH0994096A (ja) | 1997-04-08 |
JP3254127B2 (ja) | 2002-02-04 |
HK153395A (en) | 1995-10-06 |
JP3506683B2 (ja) | 2004-03-15 |
JP3217019B2 (ja) | 2001-10-09 |
JPH10113192A (ja) | 1998-05-06 |
DE3768833D1 (de) | 1991-05-02 |
JP3254128B2 (ja) | 2002-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2039233T5 (es) | Procedimientos para la produccion de glicoproteinas del citomegalovirus humano (hcmv), anticuerpos correspondientes y vacunas del hcmv, y vectores recombinantes para los mismos. | |
ATE112802T1 (de) | Herstellung von funktionellen menschlichen urokinasepolypeptiden. | |
DE3786592T3 (de) | Transformation von Trichoderma. | |
FI873141A (fi) | Daeggdjurs interleukin-4. | |
DE69230993T2 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
DZ467A1 (fr) | Interferon immunitaire urbain. | |
ES522762A0 (es) | "procedimiento para la produccion simultanea de los productos geneticos de dos o mas genes afines" | |
FR2620459B1 (fr) | Virus recombinant de la vaccine | |
FI854257L (fi) | Orala vacciner. | |
DK110190D0 (da) | Alveolaere surfaktantproteiner | |
PT88684A (pt) | Metodo de tratamento fosfatidilico de doencas virais | |
ZW11281A1 (en) | Dna sequences recombinant dna molecules and processes for producing polypeptides with the specifity of foot and mouth disease viral antigens | |
ES2076178T3 (es) | Papilomavirus humano tipo 57, su adn y las proteinas codificadas por el. | |
DE3751602D1 (de) | Subkutane Verabreichung des humanen Choriongonadotropins. | |
DE3877136D1 (de) | Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung. | |
Kukaine et al. | Induction of bovine leukemia C-type oncornaviruses | |
ATE84315T1 (de) | Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen. | |
NO880080D0 (no) | Fremgangsmaate for isolering og rensing av p.faliciparum cs-proteinvaksine uttrykt i rekombinant e.coli. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 236145 Country of ref document: ES |